ALK INHIBITOR AP26113 IN PATIENTS WITH ADVANCED MALIGNANCIES, INCLUDING ALK plus NON-SMALL CELL LUNG CANCER (NSCLC): UPDATED EFFICACY AND SAFETY DATA

被引：20
|
作者：
Gettinger, S. [1 ]
Bazhenova, L. [2 ]
Salgia, R. [3 ]
Langer, C. [4 ]
Gold, K. [5 ]
Rosell, R. [6 ]
Shaw, A. [7 ]
Weiss, G. J. [8 ]
Narasimhan, N. I. [9 ]
Dorer, D. J. [10 ]
Rivera, V. M. [11 ]
Clackson, T. [12 ]
Haluska, F. G. [13 ]
Camidge, R. [14 ]
机构：
[1] Yale Univ, Sch Med, Thorac Oncol Program, New Haven, CT USA
[2] UCSD Moores Canc Ctr, La Jolla, CA USA
[3] Univ Chicago, Dept Med, Hematol Oncol Sect, Chicago, IL 60637 USA
[4] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA
[5] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[6] USP Dexeus Univ Inst, Inst Oncol Dr Rosell, Med Oncol Serv, Barcelona, Spain
[7] Massachusetts Gen Hosp, Boston, MA 02114 USA
[8] Scottsdale Healthcare, Virginia G Piper Canc Ctr Clin Trials, Scottsdale, AZ USA
[9] ARIAD Pharmaceut Inc, DMPK, Cambridge, MA USA
[10] ARIAD Pharmaceut Inc, Biostat, Cambridge, MA USA
[11] ARIAD Pharmaceut, Preclin & Translat Res, Cambridge, MA USA
[12] ARIAD Pharmaceut Inc, Res & Dev, Cambridge, MA USA
[13] ARIAD Pharmaceut Inc, Clin Res & Dev, Cambridge, MA USA
[14] Univ Colorado, Div Med Oncol, Denver, CO 80202 USA
来源：
ANNALS OF ONCOLOGY | 2014年 / 25卷
关键词：
D O I：
10.1093/annonc/mdu349.71
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1292P
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Anti-ALK autoantibodies in patients with ALK positive non-small cell lung cancer (NSCLC)
    Parisi, C.
    Benitez, J. C.
    Lecourt, H.
    Dall'Olio, F. G.
    Aldea, M.
    Blanc-Durand, F.
    Verge, V.
    Quivoron, C.
    Naltet, C.
    Abdayem, P.
    Lavaud, P.
    Ghigna, M. R.
    Loriot, Y.
    De Botton, S.
    Planchard, D.
    Barlesi, F.
    Soria, J-C.
    Ribrag, V.
    Friboulet, L.
    Besse, B.
    ANNALS OF ONCOLOGY, 2021, 32 : S956 - S957
  • [22] Brigatinib efficacy and safety in patients (Pts) with anaplastic lymphoma kinase (ALK)-positive (ALK plus ) non-small cell lung cancer (NSCLC) in a phase 1/2 trial
    Rosell, R.
    Gettinger, S. N.
    Bazhenova, L. A.
    Langer, C. J.
    Salgia, R.
    Shaw, A. T.
    Narasimhan, N. I.
    Dorer, D. J.
    Kerstein, D.
    Camidge, D. R.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (04) : S114 - S114
  • [23] Efficacy and safety of lorlatinib in patients (pts) with ALK plus non-small cell lung cancer (NSCLC) with one or more prior ALK tyrosine kinase inhibitor (TKI): A phase I/II study
    Shaw, Alice Tsang
    Ou, Sai-Hong Ignatius
    Felip, Enriqueta
    Bauer, Todd Michael
    Besse, Benjamin
    Gadgeel, Shirish M.
    Camidge, D. Ross
    Lin, Chia-Chi
    Seto, Takashi
    Soo, Ross A.
    Chiari, Rita
    James, Leonard P.
    Clancy, Jill S.
    Martini, Jean-Francois
    Abbattista, Antonello
    Pithavala, Yazdi K.
    Solomon, Benjamin J.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [24] Symptoms of Bone and Liver Metastases in Patients with ALK plus Non-Small Cell Lung Cancer (NSCLC)
    Guerin, Annie
    Sasane, Medha
    Nitulescu, Roy
    Zhang, Jie
    Culver, Kenneth W.
    Wu, Eric Q.
    Macalalad, Alexander R.
    Dalai, Anand
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S412 - S412
  • [25] Clinical presentation of hepatotoxicity-associated crizotinib in ALK-positive (ALK plus ) advanced non-small cell lung cancer (NSCLC).
    Schnell, Patrick
    Safferman, Allan Zachary
    Bartlett, Cynthia Huang
    Tang, Yiyun
    Wilner, Keith D.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [26] Clinical experience with crizotinib in patients (pts) with advanced ALK plus non-small cell lung cancer (NSCLC) and brain metastases
    Crino, L.
    Ahn, M. J.
    Ou, S. H. I.
    Solomon, B. J.
    Costa, D. B.
    Shreeve, S. M.
    Wiltshire, R.
    Selaru, P.
    Zhou, C.
    Riely, G. J.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S800 - S800
  • [27] ALK FISH positivity and crizotinib efficacy in patients (pts) with non-small cell lung cancer (NSCLC).
    Soria, Jean-Charles
    Ho, Steffan N.
    Varella-Garcia, Marileila
    Iafrate, A. John
    Solomon, Benjamin J.
    Shaw, Alice T.
    Blackhall, Fiona Helen
    Mok, Tony
    Wu, Yi-Long
    Pestova, Ekaterina
    Siebert, Fred W.
    Wilner, Keith D.
    Polli, Anna
    Paolini, Jolanda
    Lanzalone, Silvana
    Green, Stephanie J.
    Camidge, D. Ross
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [28] AP26113 is a dual ALK/EGFR inhibitor: Characterization against EGFR T790M in cell and mouse models of NSCLC
    Rivera, Victor M.
    Wang, Frank
    Anjum, Rana
    Zhang, Sen
    Squillace, Rachel
    Keats, Jeffrey
    Miller, David
    Ning, Yaoyu
    Wardwell, Scott D.
    Moran, Lauren
    Miret, Juan
    Narasimhan, Narayana
    Dalgarno, David
    Clackson, Tim
    Shakepeare, William C.
    CANCER RESEARCH, 2012, 72
  • [29] Long-term efficacy and safety from the CROWN study in Japanese patients with ALK plus advanced non-small cell lung cancer
    Teraoka, Shunsuke
    Hayashi, Hidetoshi
    Goto, Yasushi
    Nishio, Makoto
    Sugawara, Shunichi
    Inoue, Takako
    Oizumi, Satoshi
    Kato, Terufumi
    Toyoizumi, Shigeyuki
    Matsumura, Masakazu
    Messina, Rossella
    ANNALS OF ONCOLOGY, 2023, 34 : S1418 - S1418
  • [30] ALINA: efficacy and safety of adjuvant alectinib versus chemotherapy in patients with early-stage ALK plus non-small cell lung cancer (NSCLC)
    Shah, Rajiv
    Solomon, Benjamin J.
    Ahn, Jin Seok
    Dziadziuszko, Rafal
    Barlesi, Fabrice
    Nishio, Makoto
    Lee, Dae Ho
    Lee, Jong-Seok
    Zhong, Wenzhao
    Horinouchi, Hidehito
    Mao, Weimin
    Hochmair, Maximilian
    de Marinis, Filippo
    Migliorino, Maria Rita
    Bondarenko, Igor
    Lohmann, Tania Ochi
    Xu, Tingting
    Cardona, Andres
    Bordogna, Walter
    Ruf, Thorsten
    Wu, Yi-Long
    ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 243 - 244
12345